Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Neuropace, Inc.

NPCENASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jun 22, 2026Accepted Jun 22, 2026, 4:33 PM EDTFiling CIK 1528287Accession 0001297260-26-000007
Share

Structured filing — 4

wk-form4_1782160401.xml

Open full document ↗

Filing details

Report period
2026-06-19
Issuer
NeuroPace Inc
Issuer CIK
0001528287
Trading symbol
NPCE

Reporting owner 1

Name
Fischer Frank M
Reporting owner CIK
0001297260
Relationship
Director
Address
C/O NEUROPACE, INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-06-19A · Form 41,467[F1]A15.63599,534D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.↩ 1

Signature 1

Signed
/s/ Leah Akin, Attorney-in-Fact
Date
2026-06-22

Company context

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by First Light Asset Management, LLC regarding NeuroPace IncSep 4, 2026
  2. 4 filingAug 28, 2026
  3. 10-Q filingAug 11, 2026
  4. Results of Operations and Financial ConditionAug 11, 2026
  5. Regulation FD DisclosureJul 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.